Atara Biotherapeutics Inc (ATRA) Short Interest Update

Atara Biotherapeutics Inc (NASDAQ:ATRA) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,533,903 shares, a growth of 1.6% from the March 15th total of 3,479,413 shares. Based on an average daily volume of 318,209 shares, the days-to-cover ratio is presently 11.1 days.

Atara Biotherapeutics (NASDAQ:ATRA) opened at 15.15 on Friday. The company’s market capitalization is $440.70 million. Atara Biotherapeutics has a 12 month low of $12.45 and a 12 month high of $25.73. The stock’s 50 day moving average is $16.87 and its 200-day moving average is $16.86.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, March 9th. The biotechnology company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.35. On average, analysts expect that Atara Biotherapeutics will post ($3.83) EPS for the current year.

In other Atara Biotherapeutics news, CFO John Mcgrath sold 24,000 shares of the firm’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $20.00, for a total value of $480,000.00. Following the transaction, the chief financial officer now directly owns 126,827 shares of the company’s stock, valued at $2,536,540. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gad Soffer sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $20.00, for a total transaction of $50,000.00. Following the completion of the transaction, the executive vice president now directly owns 266,527 shares in the company, valued at $5,330,540. The disclosure for this sale can be found here. Insiders have sold 142,958 shares of company stock worth $2,630,542 over the last three months. 16.10% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ATRA. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Atara Biotherapeutics during the first quarter worth approximately $132,000. Elkfork Partners LLC purchased a new position in Atara Biotherapeutics during the fourth quarter worth approximately $135,000. DekaBank Deutsche Girozentrale purchased a new position in Atara Biotherapeutics during the first quarter worth approximately $185,000. BlackRock Inc. increased its position in Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the biotechnology company’s stock worth $272,000 after buying an additional 6,597 shares in the last quarter. Finally, American International Group Inc. increased its position in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares in the last quarter. Hedge funds and other institutional investors own 77.48% of the company’s stock.

A number of equities analysts have issued reports on ATRA shares. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Saturday, March 11th. Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Finally, Citigroup Inc set a $10.00 price target on shares of Atara Biotherapeutics and gave the stock a “sell” rating in a research report on Thursday, March 16th. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $24.00.

WARNING: “Atara Biotherapeutics Inc (ATRA) Short Interest Update” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://transcriptdaily.com/2017/05/20/atara-biotherapeutics-inc-atra-short-interest-up-1-6-in-march-updated-updated-updated.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

12 Month Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply